Trials / Completed
CompletedNCT00867438
Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium, Administered Add-on Therapy
Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium (CB-01-05-MMX™), Administered as Add-on Therapy to Oral Mesalazine or Other 5-ASA Derivatives, in Patients With Active, Left-Sided, Mild to Moderate Ulcerative Colitis. A Multicentre Randomized, Double-Blind, Comparative Study Versus Placebo.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 133 (actual)
- Sponsor
- Cosmo Technologies Ltd · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the efficacy and the tolerability of oral parnaparin sodium (210mg), administered in extended-release tablets identified as CB-01-05-MMX™.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Sigmoidoscopy |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2007-11-01
- Completion
- 2007-11-01
- First posted
- 2009-03-23
- Last updated
- 2009-03-25
Source: ClinicalTrials.gov record NCT00867438. Inclusion in this directory is not an endorsement.